Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors
暂无分享,去创建一个
Rongguang Zhang | Q. Wang | Lu Lu | Shibo Jiang | S. Ye | S. Xia | Yun Zhu | F. Yu | Qianqian Qi | Shan Su | Qian Wang | Zhenxuan Ma | Rong-guang Zhang
[1] Lu Lu,et al. An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene , 2016, Emerging Microbes & Infections.
[2] W. Greene,et al. Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells. , 2015, Cell reports.
[3] Q. Wang,et al. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy , 2015, Scientific Reports.
[4] Q. Wang,et al. Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy , 2015, Journal of Virology.
[5] A. Bax,et al. Complete dissociation of the HIV-1 gp41 ectodomain and membrane proximal regions upon phospholipid binding , 2015, Journal of biomolecular NMR.
[6] Q. Wang,et al. A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. , 2014, Current pharmaceutical design.
[7] Y. Qiao,et al. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. , 2014, The Journal of antimicrobial chemotherapy.
[8] A. Bax,et al. Dissociation of the trimeric gp41 ectodomain at the lipid–water interface suggests an active role in HIV-1 Env-mediated membrane fusion , 2014, Proceedings of the National Academy of Sciences.
[9] Q. Wang,et al. An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. , 2013, The Journal of antimicrobial chemotherapy.
[10] George F. Gao,et al. Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.
[11] Shuxian Hu,et al. T-cell reconstitution during murine acquired immunodeficiency syndrome (MAIDS) produces neuroinflammation and mortality in animals harboring opportunistic viral brain infection , 2013, Journal of Neuroinflammation.
[12] Jianping Sun,et al. Short‐peptide fusion inhibitors with high potency against wild‐type and enfuvirtide‐resistant HIV‐1 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] Lu Lu,et al. 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. , 2013, The Journal of antimicrobial chemotherapy.
[14] Hong Lu,et al. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains , 2012, Retrovirology.
[15] Lu Lu,et al. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. , 2012, Biochimica et Biophysica Acta.
[16] Suiyi Tan,et al. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. , 2012, Fitoterapia.
[17] Yuxian He,et al. Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide* , 2012, The Journal of Biological Chemistry.
[18] B. Berkhout,et al. Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function , 2011, Journal of Virology.
[19] Clare Jolly,et al. Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors , 2011, Virology.
[20] Shibo Jiang,et al. Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41 , 2010, ChemMedChem.
[21] Felix Campelo,et al. Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions , 2010, PLoS pathogens.
[22] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[23] A. Debnath,et al. ADS-J1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the gp41 Pocket Region and Blocking Fusion-Active gp41 Core Formation , 2009, Antimicrobial Agents and Chemotherapy.
[24] A. Foulkes,et al. Low-Cost HIV-1 Diagnosis and Quantification in Dried Blood Spots by Real Time PCR , 2009, PloS one.
[25] S. Sarafianos,et al. SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide , 2008, Antimicrobial Agents and Chemotherapy.
[26] Shibo Jiang,et al. Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors* , 2008, Journal of Biological Chemistry.
[27] Shibo Jiang,et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains , 2008, Proceedings of the National Academy of Sciences.
[28] A. Debnath,et al. Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition , 2008, Journal of Virology.
[29] A. Debnath,et al. Conserved Salt-bridge between the Nand C-Terminal Heptad Repeat Regions of HIV-1 gp 41 Core Structure Is Critical for Virus Entry and Inhibition , 2008 .
[30] T. Matthews,et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus , 2007, Proceedings of the National Academy of Sciences.
[31] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[32] Shibo Jiang,et al. HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains , 2007, Journal of Biological Chemistry.
[33] H. I. Henderson,et al. The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection , 2006, Virology Journal.
[34] Michael S. Kay,et al. Inhibiting HIV Fusion with a β-Peptide Foldamer , 2005 .
[35] Shibo Jiang,et al. Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120* , 2005, Journal of Biological Chemistry.
[36] A. Schepartz,et al. Inhibiting HIV fusion with a beta-peptide foldamer. , 2005, Journal of the American Chemical Society.
[37] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[38] S. A. Gallo,et al. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. , 2004, Biochemistry.
[39] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[40] T. Cihlar,et al. Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein , 2003, Journal of Virology.
[41] J. Tam,et al. A facile ligation approach to prepare three-helix bundles of HIV fusion-state protein mimetics. , 2002, Organic letters.
[42] M. Matsuoka,et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. , 2002, Angewandte Chemie.
[43] A. K. Debnath,et al. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. , 2000, Biochemical and biophysical research communications.
[44] P S Kim,et al. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] Eric Hunter,et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.
[46] P. S. Kim,et al. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. , 1997, Journal of biomolecular structure & dynamics.
[47] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[48] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[49] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[50] Shibo Jiang,et al. HIV-1 inhibition by a peptide , 1993, Nature.
[51] G. Salitra,et al. Nested fullerene-like structures , 1993, Nature.
[52] J Desmyter,et al. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.